July 27, 2016 8:01 AM ET

Biotechnology

Company Overview of Genentech, Inc.

Company Overview

Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company also offers hematology medicines that include antibody-drug conjugates, small molecule antagonists, and small molecule BCL-2 inhibitors. Genentech, Inc. has a strategic alliance with Array biopharma; clinical trial collaborations with Clovis Oncology and Astex Pharmaceuticals, Inc.; and an immunotherapy trial collaboration with Immune ...

1 DNA Way Mailstop 258A

South San Francisco, CA 94080-4990

United States

Founded in 1976

11,186 Employees

Phone:

650-225-1000

Fax:

650-225-4630

Key Executives for Genentech, Inc.

Chief Executive Officer, Head of North American Commercial Operations and Director
Age: 55
Co-Founder and Member of Scientific Resource Board
Age: 79
Senior Vice President and General Counsel
Chief Compliance Officer, Head of Legal Affairs for North America, Senior Vice President and Secretary
Vice President of Human Resources and Regional Human Resources Head of North America
Compensation as of Fiscal Year 2016.

Genentech, Inc. Key Developments

Genentech Gains Access to Peptidream's Discovery Technology

Peptidream Inc. has granted non-exclusive rights to its peptide discovery platform to Roche's biotechnology subsidiary, Genentech. As part of the agreement, Peptidream will receive an undisclosed upfront payment and annual technology access fees. It is entitled to development milestones and sales royalties for products that will arise from the use of its technology. Peptidream first started its collaboration with Genentech in December 2015. The two companies are identifying peptides and optimise them into therapeutic peptides or small molecule products.

Genentech Provides Update on Phase III Study of Gazyva in People with Previously Untreated Diffuse Large B-Cell Lymphoma

Genentech announced that the Phase III GOYA study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy (G-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint of significantly reducing the risk of disease worsening or death (progression-free survival; PFS) compared to Rituxan (rituximab) plus CHOP chemotherapy (R-CHOP). Adverse events with Gazyva and Rituxan were consistent with those seen in previous clinical trials when each was combined with various chemotherapies. Data from the GOYA study will be presented at an upcoming medical meeting. GOYA (NCT01287741) is a global Phase III open-label, multicenter, randomized two-arm study examining the efficacy and safety of the combination of Gazyva plus CHOP chemotherapy (G-CHOP) compared to Rituxan plus CHOP chemotherapy (R-CHOP). GOYA included 1,418 previously untreated patients with CD20-positive DLBCL. The primary endpoint of the study is investigator-assessed PFS, with secondary endpoints including PFS assessed by independent review committee (IRC), response rate (overall response, ORR; and complete response, CR), overall survival (OS), disease free survival (DFS) and safety profile. The GOYA study is being conducted in cooperation with the Fondazione Italiana Linfomi (FIL, Italy). Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL), accounting for about one in three cases of NHL. DLBCL is an aggressive (fast-growing) type of NHL. As many as 40% of patients will relapse, at which point their prognosis is poor. In the United States, it is estimated that more than 24,000 new cases of DLBCL will be diagnosed in 2016. Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found on certain types of B-cells. It is thought to work by attacking targeted cells both directly and together with the body's immune system. Gazyva was discovered by Roche Glycart AG, a wholly owned, independent research unit of Roche. In the United States, Gazyva is part of a collaboration between Genentech and Biogen. Combination studies investigating Gazyva with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors, are planned or underway across a range of blood cancers. Patients must tell their doctor right away about any side effects they experience. Gazyva can cause side effects that can become serious or life threatening, including: Hepatitis B Virus (HBV); Progressive Multifocal Leukoencephalopathy (PML): The most common side effects of Gazyva in CLL are infusion reactions, low white blood cell counts, low platelet counts, low red blood cell counts, fever, cough, nausea, and diarrhea. The safety of Gazyva was evaluated based on 392 patients with indolent NHL (iNHL) of whom 81% had follicular lymphoma. In patients with follicular lymphoma, the most common side effects that were seen were consistent with the overall population who had iNHL. The most common side effects of Gazyva are infusion reactions, low white blood cell counts, nausea, fatigue, cough, diarrhea, constipation, fever, low platelet counts, vomiting, upper respiratory tract infection, decreased appetite, joint or muscle pain, sinusitis, low red blood cell counts, general weakness, and urinary tract infection. The most common side effects of Rituxan are infusion reactions, chills, infections, body aches, tiredness and low white blood cells. Patients must tell their doctor if they are pregnant, plan to become pregnant or are breastfeeding. It is not known if Rituxan may harm the patient’s unborn baby or pass into the patient’s breast milk. Women should use birth control while using Rituxan and for 12 months after treatment.

European Court of Justice Orders Genentech to Pay Licensing-Agreement Royalties to Sanofi

On 7 July, the European Court of Justice (ECJ) handed down a ruling ordering Genentech to pay agreed running-royalties to the German unit of Sanofi (France) under a licensing agreement. The case concerned a licensing agreement that required the licensee to pay royalties for the use of a patent that had been revoked. The ECJ ruling is a significant legal judgement, and is likely to mean that in future the beneficiary of a patent licence will be obliged to pay royalties even in the case that the company does not infringe on the patent technology in question. The ECJ interpreted the royalty as being part of the price that is paid for "commercial exploitation of the patented technology with the guarantee that the licensor will not bring legal proceedings for infringement against the licensee". The ECJ has taken the view that there is nothing to "prohibit the obligation to pay a royalty for the use of technology, even where such use does not give rise to an infringement, or the technology is deemed never to have been protected in the event of retroactive revocation of the patent". This could hold legal implications for other pharmaceutical companies, as the court ruling suggests that royalties for unpatented technology is not anticompetitive under European Union (EU) legislation. This is expected to have certain practical legal considerations, and should invite additional caution on the part of pharmaceutical companies when negotiating future licensing agreements in the EU.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Genentech, Inc., please visit www.gene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.